On Thursday, WPX Energy, Inc. (NYSE:WPX)’s shares gained 4.92%, closed at $11.74.
WPX Energy, plans to talk about its first-quarter 2015 financial and operations results during a webcast on Wednesday morning, May 6, starting at 10 a.m. Eastern.
Chief Executive Officer Rick Muncrief, Senior Vice President of Operations and Resource Development Clay Gaspar, and Chief Financial Officer Kevin Vann will talk about the corporation’s performance.
WPX Energy, Inc., an independent natural gas and oil exploration and production corporation, engages in the exploitation and development of unconventional properties in the United States.
CONSOL Energy Inc. (NYSE:CNX)’s shares jumped 4.90%, and settled at $29.09, during the last trading session on Thursday, as an integrated energy corporation, and Halliburton (HAL) declared the planned deployment of the first hydraulic fracturing spread that is fully compliant with the Environmental Protection Agency’s 2015 Tier 4F emissions standard for non-road, high-horsepower engines. Tier 4F equipment will be used to complete fracturing jobs on all six pads on Pittsburgh International Airport (PIT) property.
Completions on Pad 2 at PIT commence recently with an predictable 36% overall reduction in emissions as a result of this new equipment.
Halliburton teamed up with Cummins to maximize the use of the Tier 4F engines. In addition to building a spread that is fully Tier 4F-compliant, Halliburton is also utilizing its existing emissions-reducing technologies on site, counting the solar panel-powered SandCastle® PS-2500 Vertical Proppant Storage System.
CONSOL Energy Inc., together with its auxiliaries, operates as an integrated energy corporation in the United States and internationally. The corporation operates through two divisions, Exploration and Production (E&P), and Coal.
At the end of Thursday’s trade, Oi S.A. (NYSE:OIBR)’s shares climbed 4.86%, and closed at $1.94, after the corporation declared it would eliminate more than 1,000 jobs and raise shareholder rights in an effort to turn around the corporation.
The Rio de Janeiro-based corporation declared Wednesday that it had reduced personnel expenses by 20% as part of its 2015 plan that centers on cost control.
The corporation’s changes could assist Oi, Brazil’s smallest wireless provider, become a potential suitor or takeover target in the telecom industry, according to Bloomberg.
Repros Therapeutics Inc. (NASDAQ:RPRX), ended its Thursday’s trading session with 4.59% gain, and closed at $8.88, as a development stage biopharmaceutical corporation, declared the New Drug Application (NDA) for its enclomiphene citrate product candidate, formerly known as Androxal(R), has been accepted by the U.S. Food and Drug Administration (FDA), indicating that the application is sufficiently complete to permit a substantive review. This investigational product, which is the Corporation’s lead product candidate, is a single isomer of clomiphene citrate and an orally active proprietary small molecule compound. The Corporation is developing this product candidate for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. Men with secondary hypogonadism exhibit low testosterone levels due to under stimulated testes but they are generally fertile. The Corporation’s product candidate is designed to treat the underlying mechanism, insufficient stimulation of the testes by the pituitary, which causes secondary hypogonadism.
Repros Therapeutics focuses on the development of small molecule drugs for major unmet medical needs that treat male and female reproductive disorders. The corporation has a license contract with the National Institutes of Health to develop and commercialize Proellex. Repros Therapeutics Inc. was founded in 1987 and is based in The Woodlands, Texas.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
